Annotation Detail
Information
- Associated Genes
- FGFR3
- Associated Variants
-
FGFR3 MUTATION
FGFR3 MUTATION - Associated Disease
- transitional cell carcinoma
- Source Database
- CIViC Evidence
- Description
- In a phase 2 trial, patients with locally advanced and unresectable or metastatic urothelial carcinoma harboring FGFR3 mutation or FGFR2/3 fusion were treated with Erdafitinib. All the patients had a history of disease progression during or after at least one course of chemotherapy. The response rate in all patients was 40% (40/99). The response rate in patients with FGFR3 mutation was 49% (36/74). FGFR3 mutations included G370C, R248C, S249C, Y373C, and R48C.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/7422
- Gene URL
- https://civic.genome.wustl.edu/links/genes/23
- Variant URL
- https://civic.genome.wustl.edu/links/variants/827
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Urothelial Carcinoma
- Evidence Direction
- Supports
- Drug
- Erdafitinib
- Evidence Level
- A
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 31340094
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Erdafitinib | Sensitivity | true |